Over 900 FDA-approved AI-enabled devices exist, with companies like Johnson & Johnson and AbbVie leveraging AI for drug discovery. AI market growth is projected to increase significantly ...

Machine learning in drug discovery, along with artificial intelligence, is transforming the pharmaceutical industry by accelerating the development of new treatments. Historically, the process of ...

Drug discovery has traditionally been slow and expensive, often taking decades and costing manufacturers billions. Traditional methods, while advancing, are hitting limits in tackling the ...

Iambic, which has previously won investment from tech giant Nvidia, published details of its new AI drug discovery model, named "Enchant". Enchant was trained on large troves of pre-clinical data ...

Artificial intelligence (AI) and machine learning (ML) are promising tools for enhancing R&D. In drug discovery, AI can perform a variety of tasks, from identifying potential drug targets to ...

Simply sign up to the Artificial intelligence myFT Digest -- delivered directly to your inbox. Isomorphic Labs, the drug discovery start-up led by Sir Demis Hassabis, has accelerated spending on ...

In addition to a variety of other in-house A.I. models, AlphaFold 3 is one of the tools used by Isomorphic Labs to advance internal drug discovery projects. As the startup’s efforts grow ...

This database already contains further data on the human microbiota, which will allow us to discover many new natural products and use them as a basis for drug development." The pharmacists ...

Iambic, which has previously won investment from tech giant Nvidia, published details of its new AI drug discovery model, named "Enchant". Enchant was trained on large troves of pre-clinical data ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger ...